Have You Been Harmed By One Of The Drugs Or Other Medical Products Covered On This Site?

If so, you may have a possible legal case against the manufacturer of the potentially dangerous drug or medical product. Simply fill out the short form below and an experienced legal expert will contact you as soon as possible!

First Name:

Last Name:

Street Address:

City:

State:

Zip:

Daytime Phone Number:

Alternate Phone Number (Optional):

E-Mail Address:



Is this request for you or someone else?
Myself
My Spouse or
Minor Child
Other Relative or Friend

Drug Or Device Exposed To:


Dates Taken:


Related Health Problems Caused By The Drug:


FDA Deciding Upon Weight Loss Drug Labelling

Added March 31st, 2005

Meridia, manufactured by Abbot Laboratories, was approved as the new wonder pill for weight loss shortly after another diet pill, Fen-Phen, had been recalled from the US market due to the dangerous side effects connected to it. Despite opposition from some of the FDA’s own officials, Meridia was approve in 1998, and within a year, two million prescriptions had been issued for this diet pill.

This new pill was heavily marketed, and the manufacturers tried to distance it as much as possible from its predecessor, Fen-Phen. However, despite claims that this new diet wonder pill was as safe and reliable as they come, it wasn’t long before reports of adverse effects caused by Meridia started to roll in.

In March 2002 Public Citizen, the health group, petitioned the FDA to remove Meridia from the US market. This followed a string of reports of serious and deadly side effects, which included nearly thirty deaths linked to Meridia, and a range of heart problems.

The FDA is now looking into strengthened labelling for the weight loss drug, and it is thought that the agency is close to issuing a health advisory on the drug. This comes after the controversy that has shrouded both the drug and the FDA because of the initial approval of a drug with such potentially deadly side effects. It is though that the health advisory issued could affect prescribing guidelines, dosage, and stronger warnings about side effects.

FDA Deciding Upon... | Printable Version (Opens In New Window)


Important Notice: RYAR.org is a legal informational site.The content contained herein was not prepared by lawyers and should not be taken as a substitute for legal advice from a licensed attorney. Additionally, this information is not intended to create an attorney-client relationship simply by its viewing. The creation of an attorney-client relationship requires more than viewing this or affiliated websites. Neither the transmission nor receipt of this website material will create an attorney-client relationship between sender and receiver. The material contained herein is general in nature and may or may not be applicable to a viewer’s individual legal needs. Online readers should not act on this information without seeking professional counsel. Please read our 'Terms & Conditions Of Use' for more information.

Additionally, the information contained on RYAR.org, including but not limited to informational articles, other text/images, and on or off site links, has not been prepared, endorsed, or reviewed by any form of licensed medical professional, including but not limited to physicians, doctors, and so on. Nothing on the this website should be taken as medical advice, but instead should act as a useful resource in providing general information that may be useful to members of the general public. All visitors are encouraged to consult with a physician or other licensed medical professional for any form of medical advice. Please see our 'Terms & Conditions Of Use' for further information